Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

First International Summit on Interventional Pharmacoeconomics

David A. Hyman, MD, JD, on Inclusive Shared Savings

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Deborah Collyar: What's In It for Patients?

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Issues in Oncology

The ASCO Post Staff

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Mar

Today In Oncology

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Deborah Collyar: What's In It for Patients?

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Black Patients With AML Face Younger Onset and Significantly Worse Survival Outcomes

CD123-Targeting ADC Shows Activity in AML and BPDCN

Combined Tests Could Avoid Unnecessary Cystectomy, Study Finds

Adjuvant Pembrolizumab Plus Belzutifan in Patients With RCC at Increased Risk of Recurrence

Research Suggests AI Pathology Models May Take Unreliable Shortcuts to Identify Cancer Biomarkers